Release Date: 29 January 2025
Targeted alpha therapy (TAT) is swiftly gaining recognition as a highly promising and innovative treatment option in the realm of oncology. This approach provides a precise and effective means of targeting cancer cells, s...
Release Date: 25 January 2025
CBP-1008, developed by Coherent Biopharma, is a first-in-class bispecific ligand drug conjugate (Bi-XDC) targeting both folate receptor andalpha; (FRandalpha;) and TRPV6, which are overexpressed in various solid tumors, i...
Release Date: 25 January 2025
A166, developed by KLUS Pharma, is a third-generation antibody-drug conjugate (ADC) designed to target HER2-positive cancers. It consists of a humanized anti-HER2 antibody, identical to trastuzumab, conjugated to a potent...
Release Date: 25 January 2025
B003 is an antibody-drug conjugate (ADC) developed by Shanghai Pharmaceuticals Holding, a Chinese pharmaceutical entity. It comprises a recombinant humanized anti-HER2 monoclonal antibody linked to the potent maytansinoid...
Release Date: 25 January 2025
BL-M02D1 is an antibody-drug conjugate (ADC) produced by Bai-Li Pharmaceutical, a biopharmaceutical company in China, which targets TROP2, a cell surface protein that is overexpressed in various solid tumors. Utilizing th...
Release Date: 25 January 2025
RC108 is an antibody-drug conjugate (ADC) from RemeGen, a Chinese biopharmaceutical enterprise, which targets c-Met, a receptor tyrosine kinase. The activation of c-Met by its ligand, hepatocyte growth factor, initiates s...
Release Date: 25 January 2025
YL-201 is an antibody-drug conjugate (ADC) developed by MediLink, a biopharmaceutical company from China, utilizing its proprietary TMALIN platform. This innovative platform aims to overcome the limitations of current ADC...
Release Date: 25 January 2025
SHR-A2009 is an antibody-drug conjugate (ADC) developed by Suzhou Suncadia Biopharmaceuticals, a subsidiary of Jiangsu HengRui Medicine, a Chinese biopharmaceutical firm. It features a human IgG1 monoclonal antibody that ...
Release Date: 25 January 2025
DX126-262 is an ADC created by Hangzhou DAC Biotech, a Chinese biopharmaceutical firm. This drug comprises a recombinant humanized anti-HER2 monoclonal antibody, DX-CHO9 (IgG1), linked to Tub114, a potent cytotoxic agent,...
Release Date: 25 January 2025
RC88 is an antibody-drug conjugate (ADC) developed by RemeGen, a biopharmaceutical company based in China, which targets mesothelin (MSLN), a cell surface protein that is overexpressed in several cancers, including ovaria...
Release Date: 25 January 2025
HS-20089 represents a novel antibody-drug conjugate (ADC) developed by Hansoh Pharma in partnership with GSK, specifically aimed at treating gynecologic cancers. This investigational agent targets B7-H4, a transmembrane g...
Release Date: 25 January 2025
BNT326/YL202 is a next-generation antibody-drug conjugate (ADC) being jointly developed by BioNTech, a biotechnology company from Germany, and Bio-Thera, a biopharmaceutical firm located in China. This investigational age...
Release Date: 25 January 2025
BAT8006 is an experimental antibody-drug conjugate (ADC) developed by Bio-Thera, a biopharmaceutical company based in China. This targeted therapy is aimed at Folate Receptor-alpha (FRandalpha;), a protein that is overexpressed in variou...
Release Date: 25 January 2025
Ac-225-Rosopatamab represents an innovative targeted therapy developed through a partnership between Convergent Therapeutics and AIkido Pharma (now known as Dominari Holdings). This pioneering medication integrates a mono...
Release Date: 25 January 2025
HS-20093 is a novel antibody-drug conjugate (ADC) developed by Hansoh Pharmaceutical, a company located in China. It features a fully humanized anti-B7-H3 monoclonal antibody that is linked to a topoisomerase inhibitor (T...